71526-83-5

Basic information

• Product Name: 4-chloro-4'-ethylbutyrophenone
• Synonyms: 4-chloro-4'-ethylbutyrophenone;4-Chloro-1-(4-ethylphenyl)-1-butanone;4'-Ethyl-γ-chlorobutyrophenone
• CAS NO: 71526-83-5
• Molecular Formula: C₁₂H₁₅ClO
• Molecular Weight: 210.6999
• EINECS: 275-597-6
• Mol File: 71526-83-5.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-chloro-4'-ethylbutyrophenone(CAS DataBase Reference)
• NIST Chemistry Reference: 4-chloro-4'-ethylbutyrophenone(71526-83-5)
• EPA Substance Registry System: 4-chloro-4'-ethylbutyrophenone(71526-83-5)

Safety Data

• Hazardous Substances Data: 71526-83-5(Hazardous Substances Data)

Usage

Description

4-chloro-4'-ethylbutyrophenone, also known as 4-CEBP or 1-(4-chlorophenyl)-1-pentanone, is a synthetic chemical compound with the molecular formula C12H15ClO. It is a pale yellow liquid with a slight odor and is soluble in organic solvents such as ethanol and acetone. As a versatile compound, it plays a significant role in the field of organic chemistry as a reagent and building block in the synthesis of other compounds. However, due to its hazardous nature, it requires careful handling to mitigate potential health and environmental risks.

Uses

Used in Pharmaceutical Industry:
4-chloro-4'-ethylbutyrophenone is used as an intermediate in the production of pharmaceuticals for its ability to be a key component in the synthesis of various medicinal compounds.
Used in Organic Chemistry Research:
In the field of organic chemistry, 4-CEBP is utilized as a reagent and building block, contributing to the development and synthesis of a wide range of organic compounds for research and commercial applications.
Used in Chemical Synthesis:
4-chloro-4'-ethylbutyrophenone is employed as a versatile intermediate in chemical synthesis processes, enabling the creation of diverse organic compounds for various industries.

Upstream product

• 100-41-4 ethylbenzene 
• 4635-59-0 4-Chlorobutanoyl chloride 

Downstream Products

• 888472-02-4 4-(4'-(hydroxy(diphenyl)methyl)piperidin-1-yl)-1-(4-ethylphenyl)butan-1-one 
• 80087-35-0 1-methyl-5-[3-(4-ethylbenzoyl)propyl]thio-1,2,3,4-tetrazole 
• 71526-91-5 1-(4-Ethyl-phenyl)-4-(2-hydroxy-1-methyl-2-phenyl-ethylamino)-butan-1-one 
• 71526-96-0 1-(4-Ethyl-phenyl)-4-(4-hydroxy-butylamino)-butan-1-one 
• 71526-89-1 1-(4-Ethyl-phenyl)-4-(2-hydroxy-propylamino)-butan-1-one 
• 71526-85-7 1-(4-Ethyl-phenyl)-4-(2-hydroxy-ethylamino)-butan-1-one 
• 50664-71-6 cyclopropyl 4-ethylphenyl ketone 
• 75343-36-1 3-(4-Ethyl-phenyl)-1-phenyl-1,4,5,6-tetrahydro-pyridazine 
• 71526-82-4 9a-(4-ethyl-phenyl)-octahydro-pyrrolo[2,1-b][1,3]oxazepine 
• 71526-79-9 7a-(4-ethyl-phenyl)-3-methyl-2-phenyl-hexahydro-pyrrolo[2,1-b]oxazole 

Relevant articles and documents

Structure-based design of haloperidol analogues as inhibitors of acetyltransferase Eis from: Mycobacterium tuberculosis to overcome kanamycin resistance

Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a deadly bacterial disease. Drug-resistant strains of Mtb make eradication of TB a daunting task. Overexpression of the enhanced intracellular survival (Eis) protein by Mtb confers resistance to the second-line antibiotic kanamycin (KAN). Eis is an acetyltransferase that acetylates KAN, inactivating its antimicrobial function. Development of Eis inhibitors as KAN adjuvant therapeutics is an attractive path to forestall and overcome KAN resistance. We discovered that an antipsychotic drug, haloperidol (HPD, 1), was a potent Eis inhibitor with IC50 = 0.39 ± 0.08 μM. We determined the crystal structure of the Eis-haloperidol (1) complex, which guided synthesis of 34 analogues. The structure-activity relationship study showed that in addition to haloperidol (1), eight analogues, some of which were smaller than 1, potently inhibited Eis (IC50 ≤ 1 μM). Crystal structures of Eis in complexes with three potent analogues and droperidol (DPD), an antiemetic and antipsychotic, were determined. Three compounds partially restored KAN sensitivity of a KAN-resistant Mtb strain K204 overexpressing Eis. The Eis inhibitors generally did not exhibit cytotoxicity against mammalian cells. All tested compounds were modestly metabolically stable in human liver microsomes, exhibiting 30-60% metabolism over the course of the assay. While direct repurposing of haloperidol as an anti-TB agent is unlikely due to its neurotoxicity, this study reveals potential approaches to modifying this chemical scaffold to minimize toxicity and improve metabolic stability, while preserving potent Eis inhibition. This journal is

Design and synthesis of selective, high-affinity inhibitors of human cytochrome P450 2J2

The active site topology, substrate specificity, and biological roles of the human cytochrome P450 CYP2J2, which is mainly expressed in the cardiovascular system, are poorly known even though recent data suggest that it could be a novel biomarker and potential target for therapy of human cancer. This paper reports a first series of high-affinity, selective CYP2J2 inhibitors that are related to terfenadine, with Ki values as low as 160 nM, that should be useful tools to determine the biological roles of CYP2J2.

Intermediates useful for the preparation of antihistaminic piperidine derivatives

The present invention is related to a novel intermediates and processes which are useful in the preparation of certain antihistaminic piperidine derivatives of the formula wherein W represents -C(=O)- or -CH(OH)-; R1 represents hydrogen or hydroxy; R2 represents hydrogen; R1 and R2 taken together form a second bond between the carbon atoms bearing R1 and R2; n is an integer of from 1 to 5; m is an integer 0 or 1; R3 is -COOH or -COOalkyl wherein the alkyl moiety has from 1 to 6 carbon atoms and is straight or branched each of A is hydrogen or hydroxy; and pharmaceutically acceptable salts and individual optical isomers thereof, with the proviso that where R1 and R2 are ta to form a second bond between the carbon R1 and R2 or where R1 represented hydroxy integer 0.